INOVIQ Limited and Promega Corporation announced a joint marketing agreement to co-market INOVIQ’s EXO-NET® exosome capture technology and Promega Nucleic Acid purification systems worldwide. INOVIQ and Promega have formalized a global joint marketing agreement that will offer exosome solutions for manual and high-throughput exosome isolation and nucleic acid extraction to researchers and industry for exosome-based biomarker discovery and diagnostics development. This agreement combines the expertise of global biotechnology leader Promega in the creation, production and marketing of an extensive range of research tools, technologies and automation solutions, with INOVIQ’s disruptive EXO-NET technology, exosome capture tools and exosome-based diagnostics expertise.

Under the agreement, global customers will be offered a wide range of Promega manual and automated nucleic acid extraction reagents and instruments combined with INOVIQ’s EXO-NET exosome capture tools to enable their exosome isolation, biomarker discovery and diagnostics research. Deliverables in the agreement relate to co-marketing materials and activities for INOVIQ and Promega products. The initial term of the agreement is three years, with one-year automatic renewals unless terminated by either party.

Furthermore, INOVIQ and Promega anticipate expanding the agreement to cover a range of exosome solutions for exosome isolation, characterisation and analysis kits, and instruments. Both INOVIQ and Promega are poised to leverage their expertise and resources to advance exosome-based biomarker discovery and diagnostics development, further contributing to the field of precision medicine.